Vibrant Gastro Hires Seasoned GI Executives

New CEO, Chief Medical Officer to scale company that developed drug-free, FDA-approved treatment for chronic constipation OCTOBER 19, 2023 — BOSTON — Vibrant Gastro, which developed a groundbreaking drug-free treatment for chronic constipation, has hired new executive leadership to scale the company following its FDA approval and availability by prescription. Joining the company are CEO […]

New Data Shows Vibrating Capsule (Vibrant®) Provides Predictable Time to Relief of Constipation Symptoms Among Adults with Severe Chronic Idiopathic Constipation

NEWTON, MA, May 8, 2023 – Vibrant Gastro, a medical technology company that developed an FDA-cleared drug-free treatment for chronic idiopathic constipation (CIC) in adults, today presented an abstract at the 2023 Digestive Disease Week Conference in Chicago. Vibrant® uses gentle vibrations to mechanically stimulate the colon causing the colon to contract and effectively propel […]

IT Awards 2022

Exciting news! Vibrant Gastro has won the @Israeli IT Award People & Computers 2022 for our Salesforce project in the digital transformation and innovation category. We are honored to be recognized for leveraging technology to drive growth and enhance customer experiences.

Drug-free relief from chronic constipation may come from a new vibrating pill

People who struggle with chronic constipation have a new drug-free option to help get things moving again. It’s a first-of-its-kind capsule about is the size of a regular pill – but instead of releasing medication after it’s swallowed, it vibrates to stimulate the colon. The capsules, called Vibrant, was cleared by the US Food and […]

FDA grants marketing authorization for Vibrant®, a new first-in-class, drug-free treatment for adults with chronic idiopathic constipation

Vibrant Gastro Inc. announced today that the Food and Drug Administration (FDA) granted marketing authorization for the Vibrant®, an orally administered drug-free capsule, for the treatment of adults with chronic idiopathic constipation who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. Vibrant®’s […]

A vibrating pill for constipation heads to the FDA after completing phase 3 study

A small, vibrating pill designed to help people with chronic constipation cleared a clinical study and is headed to the FDA for final review. Vibrant Gastro is putting forward its approach as a drug-free alternative for infrequent or difficult bowel movements. Swallowed along with a glass of water, the disposable pill—about the size of an […]

Vibrant’s Novel Drug-Free Treatment Demonstrates Positive Efficacy and Safety Results in Adults with Chronic Idiopathic Constipation in Pivotal Phase 3 Study

The Phase 3 data met all primary endpoints for complete spontaneous bowel movements (CSBMs) per week and showed significant improvement in secondary outcomes versus placebo Data validates Vibrant as a safe and well-tolerated option to address unmet treatment needs in chronic idiopathic constipation (CIC) Company submitted Phase 3 data to the U.S. Food and Drug […]

Vibrant Gastro Received Honorable Mention in Health Category of Fast Company’s 2022 World-Changing Ideas Awards

Vibrant Gastro received honorable mention in the health category for its innovative drug-free treatment for chronic constipation utilizing an entirely different approach compared to traditional drug-based treatments. The winners of Fast Company’s 2022 World Changing Ideas Awards were announced today, honoring clean technology, innovation in healthcare, brave new designs for cities and buildings, and other […]

Vibrant to Present Phase III Data at the 2022 Digestive Disease Week (DDW) Conference

YOKNEAM ILLIT, Israel, April 13, 2022 /PRNewswire/ — Vibrant, a medical technology company that developed a proprietary, biocompatible treatment for chronic idiopathic constipation (CIC), announced today that an abstract titled, “Efficacy and Safety of Vibrant® Capsule for Chronic Idiopathic Constipation (CIC): Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase III Trial” has been accepted for an abstract presentation at the 2022 […]